U.S., April 26 -- ClinicalTrials.gov registry received information related to the study (NCT06944145) titled 'New Treatment Strategies and Epigenetic Biomarker for Management of BPH' on March 25.
Brief Summary: SRD5A2 is a critical enzyme for prostatic development and growth, and the SRD5A2 inhibitor, finasteride, is used to treat benign prostatic hyperplasia (BPH). SRD5A2 is absent in 30% of normal adult men, which explains the resistance of a subset of patients to this commonly prescribed drug. This project proposes new combination therapies (5-ARI+raloxifene) and evaluates novel non-invasive biomarkers, based on alternative pathways that lead to prostatic enlargement.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
B...